This would be in line with the concept that FGF23 may be a mediator of phosphate toxicity, at least on the heart in a setting of CKD [36], and in that scenario targeting FGF23 by any means, besides addressing hyperphosphatemia, would be beneficial. This evidence concerns the gene FGF23 and hyperphosphatemia.